Scholarlink

Background <p>The incidence of asymptomatic hyperuricemia is rising, and there are no simple and effective indicators for identifying patients at high risk of subclinical crystal deposition. Our study explores the value of the urate deposition index (UDI) as a classification tool for risk stratification in asymptomatic hyperuricemia (AH).</p> Methods <p>Male participants with AH who visited from June 2021 to December 2025 were enrolled. After applying inclusion and exclusion criteria, 654 participants were included. Clinical data, including age, serum urate, AH duration, homocysteine levels, 24-h urinary serum urate excretion, and hypertension history, were collected. Participants were divided into positive and negative groups based on dual-energy CT (DECT) scans indicating the presence or absence of urate crystals in the joints of both feet. Statistical analyses were performed to identify independent clinical factors associated with monosodium urate (MSU) deposition and to evaluate the diagnostic efficacy of the UDI.</p> Results <p>Among the 654 participants, 342 (52.29%) tested positive for joint urate crystals. Compared to the negative group, the positive group had a longer duration of hyperuricemia and higher UDI (<i>P</i> &lt; 0.05). Logistic regression analysis revealed that UDI is a significant marker associated with the risk of joint urate crystal formation (<i>P</i> &lt; 0.05). ROC curve analysis showed an area under the curve (AUC) of 0.814 for the UDI.</p> Conclusion <p>The UDI can be used as a risk stratification tool for patients with AH, as it is a statistical indicator that reflects MSU deposition in joints. Therefore, this index has high value in identifying high-risk patients who may benefit from closer monitoring or earlier therapeutic evaluation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The urate deposition index as a classification tool for identifying subclinical monosodium urate deposition in patients with hyperuricemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月28日

查看全文
  • Jingyu Li,
  • Xue Li,
  • Zhaowen Wang,
  • Rongxuan Ye,
  • Shengkai Ye

摘要

Background

The incidence of asymptomatic hyperuricemia is rising, and there are no simple and effective indicators for identifying patients at high risk of subclinical crystal deposition. Our study explores the value of the urate deposition index (UDI) as a classification tool for risk stratification in asymptomatic hyperuricemia (AH).

Methods

Male participants with AH who visited from June 2021 to December 2025 were enrolled. After applying inclusion and exclusion criteria, 654 participants were included. Clinical data, including age, serum urate, AH duration, homocysteine levels, 24-h urinary serum urate excretion, and hypertension history, were collected. Participants were divided into positive and negative groups based on dual-energy CT (DECT) scans indicating the presence or absence of urate crystals in the joints of both feet. Statistical analyses were performed to identify independent clinical factors associated with monosodium urate (MSU) deposition and to evaluate the diagnostic efficacy of the UDI.

Results

Among the 654 participants, 342 (52.29%) tested positive for joint urate crystals. Compared to the negative group, the positive group had a longer duration of hyperuricemia and higher UDI (P < 0.05). Logistic regression analysis revealed that UDI is a significant marker associated with the risk of joint urate crystal formation (P < 0.05). ROC curve analysis showed an area under the curve (AUC) of 0.814 for the UDI.

Conclusion

The UDI can be used as a risk stratification tool for patients with AH, as it is a statistical indicator that reflects MSU deposition in joints. Therefore, this index has high value in identifying high-risk patients who may benefit from closer monitoring or earlier therapeutic evaluation.